PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.49%
Negative revenue growth while MRVL stands at 4.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
13.22%
Gross profit growth above 1.5x MRVL's 3.82%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
597.37%
EBIT growth above 1.5x MRVL's 8.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
634.21%
Operating income growth above 1.5x MRVL's 15.99%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
215.38%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
233.33%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
233.33%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.18%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.46%
Reduced diluted shares while MRVL is at 1.17%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
3.22%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
82.20%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
146.94%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
9.50%
10Y revenue/share CAGR under 50% of MRVL's 56.20%. Michael Burry would suspect a lasting competitive disadvantage.
-11.69%
Negative 5Y CAGR while MRVL stands at 109.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-40.47%
Negative 3Y CAGR while MRVL stands at 25.49%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
100.19%
5Y OCF/share CAGR above 1.5x MRVL's 45.44%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
6.52%
3Y OCF/share CAGR under 50% of MRVL's 63.72%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
43.07%
Below 50% of MRVL's 653.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
1.45%
Below 50% of MRVL's 220.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-45.24%
Negative 3Y CAGR while MRVL is 202.86%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
137.33%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
51.12%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
93.58%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
33.51%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
2.52%
Our short-term dividend growth is positive while MRVL cut theirs. John Neff views it as a comparative advantage in shareholder returns.
-11.07%
Firm’s AR is declining while MRVL shows 11.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-19.26%
Inventory is declining while MRVL stands at 4.05%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.61%
Positive asset growth while MRVL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
1.34%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-0.15%
We’re deleveraging while MRVL stands at 3.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.90%
Our R&D shrinks while MRVL invests at 1.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-31.95%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.